Quantcast

Latest Treatment of schizophrenia Stories

2011-04-11 07:00:00

TITUSVILLE, N.J., April 11, 2011 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) on April 6 approved INVEGA® (paliperidone) extended-release tablets for the treatment of schizophrenia in adolescents 12 to 17 years of age. The efficacy of INVEGA® to treat schizophrenia in adolescents was established in one six-week clinical study. INVEGA® is an atypical antipsychotic medication and was first approved in the U.S. in December...

2011-04-04 15:46:00

BEERSE, Belgium, April 4, 2011 /PRNewswire/ -- Janssen EMEA -- New data from an independent prospective study presented last week at the 19th European Congress of Psychiatry (EPA 2011) shows treatment with Risperdal® Consta® (risperidone long-acting injection (RLAI)) is associated with a lower risk of hospitalisation in patients with schizophrenia compared to treatment with other antipsychotics over a 12-month period. The data was collected as part of the...

2011-02-23 17:44:13

Newly identified gene mutation has potential for the development of more effective treatment of Schizophrenia In a major advance for schizophrenia research, an international team of scientists led by the University of California, San Diego School of Medicine and involving Trinity College Dublin researchers has identified a gene mutation strongly linked to schizophrenia that may be an important new target for the development of drug therapies. The findings are just published in the online...

2011-02-07 21:48:47

Patients with schizophrenia who take antipsychotic medications appear to lose a small but measurable amount of brain tissue over time, according to a report in the February issue of Archives of General Psychiatry, one of the JAMA/Archives journals. Schizophrenia affects 1 percent of the worldwide population and remains a leading cause of chronic disability among young adults, according to background information in the article. Progressive changes in brain volume observed in patients with...

2010-11-19 07:00:00

ORLANDO, Fla., Nov. 19, 2010 /PRNewswire/ -- Schizophrenia is a chronic and disabling brain disorder that affects 1 percent of the U.S. population and results in substantial medical and societal costs, in particular from use of health-care resources. It also can have devastating health-related and social effects on people with the disease, their families and caregivers. A pre-specified analysis from a longer-term clinical study presented at the U.S. Psychiatric and Mental Health Congress...

2010-11-17 10:00:00

SAN DIEGO, Nov. 17, 2010 /PRNewswire/ -- It's estimated that about 275,000 people in California, including 9,500 people in San Diego, are diagnosed with schizophrenia, a chronic and often disabling brain disorder. Living with schizophrenia is the topic of an upcoming public forum, including perspectives of people with schizophrenia, caregivers, experts and advocates. The event will take place on Saturday, December 4, 2010, from 11:30 a.m. to 2 p.m. at the Doubletree Hotel San Diego/Mission...

2010-11-12 13:09:15

Findings indicate two drugs of same class carry no difference in risk of mortality, a help for prescribing physicians The potential for harmful side effects associated with anti-psychotic medications for treating schizophrenia is a frustration for mental-health professionals who must balance this with the positive benefits of drugs. For example, the issue of the antipsychotic drug ziprasidone lengthening the QTc interval, a possible indicator of life-threatening heart arrhythmias, has...

2010-10-20 00:00:00

Offered as a simultaneous webcast and telephone audioconference premiering Tuesday, November 16, 2010, from 12:00 p.m.-1:30 p.m. ET, the continuing education activity seeks to distinguish benefits and risks of various pharmacological therapies in the treatment of schizophrenia and provide strategies for use in clinical practice to improve functional outcome and overall quality of life for patients affected by schizophrenia. Rockville, MD (PRWEB) October 19, 2010 CME Outfitters, LLC, (CMEO)...

2010-07-29 08:00:00

NEW YORK, July 29 /PRNewswire/ -- Intra-Cellular Therapies, Inc. today announced the results from a Phase Ib/II clinical trial in patients with schizophrenia with ITI-007, the Company's unique, investigational new drug for the treatment of schizophrenia. The trial met its primary endpoint demonstrating that ITI-007 was safe and well-tolerated in patients with stabilized schizophrenia. In addition, several exploratory endpoints were evaluated. Treatment with ITI-007 yielded important...

2010-05-24 07:00:00

TITUSVILLE, N.J., May 24 /PRNewswire/ -- According to a new survey sponsored by Janssen,® Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, 80 percent of patients with schizophrenia, a chronic, severe and disabling brain disorder, say their psychiatrists do well or very well in treating them with courtesy and respect. This positive relationship is particularly important in treating schizophrenia as patients and psychiatrists must work closely together to determine...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related